Cardio-spect

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Brand Names
Cardiolite
Generic Name
Tetrakis(2-methoxyisobutylisocyanide)copper(I) tetrafluoroborate
Commonly known or available as Cardio-spect
DrugBank Accession Number
DB14106
Background

Tetrakis (2-methoxyisobutylisocyanide) copper (I) tetrafluoroborate is a component of Cardiolite, a technetium Tc99m-based imaging agent used for assessing myocardial perfusion.1

Type
Small Molecule
Groups
Approved
Structure
Weight
Average: 602.99
Monoisotopic: 602.268772
Chemical Formula
C24H44BCuF4N4O4
Synonyms
  • Cardio-spect
  • Tetrakis (2-methoxyisobutyl isonitrile) copper (I) tetrafluoroborate

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Indication TypeIndicationCombined Product DetailsApproval LevelAge GroupPatient CharacteristicsDose Form
Diagnostic agentAngina pectoris•••••••••••••••••••••• ••••••• ••• ••••••••
Diagnostic agentBreast cancer•••••••••••••••••••••• ••••••• ••• ••••••••
Used in combination as diagnostic agentCoronary artery diseaseCombination Product in combination with: Technetium Tc-99m (DB14227)••••••••••••
Diagnostic agentCoronary artery disease (cad)•••••••••••••••••••••• ••••••• ••• ••••••••
Diagnostic agentHyperparathyroidism••••••••••••••••••• •••••••••••••••• •••••• ••••••••••••••••••••••••• ••••••• ••• ••••••••
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
No interactions found.

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Brand Name Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
CardioliteInjection, powder, lyophilized, for solution1 mg/1mLIntravenousLantheus Medical Imaging, Inc.1990-12-20Not applicableUS flag
Kit for the Preparation of Technetium Tc99m SestamibiInjection, powder, lyophilized, for solution1 mg/1mLIntravenousLantheus Medical Imaging, Inc.1990-12-20Not applicableUS flag
SestamibiInjection, powder, lyophilized, for solution1.5 mg/1IntravenousAnazao Health Corporation2012-05-23Not applicableUS flag
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
Technetium Tc 99m SestamibiInjection1 mg/1mLIntravenousCurium US LLC2011-10-31Not applicableUS flag
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
STAMICIS 1 mg Kit for Radiopharmaceutical PreparationKit1 mgQUANTARAD TECHNOLOGIES SDN BHD2020-09-082024-06-28Malaysia flag
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
SestamibiTetrakis(2-methoxyisobutylisocyanide)copper(I) tetrafluoroborate (1.5 mg/1)Injection, powder, lyophilized, for solutionIntravenousAnazao Health Corporation2012-05-23Not applicableUS flag

Categories

Drug Categories
Not Available
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
N6OU7HJ70P
CAS number
103694-84-4
InChI Key
WJRFSUVOHUMYAO-UHFFFAOYSA-N
InChI
InChI=1S/4C6H11NO.BF4.Cu/c4*1-6(2,8-4)5-7-3;2-1(3,4)5;/h4*5H2,1-2,4H3;;/q;;;;-1;+1
IUPAC Name
lambda1-copper(1+) tetrakis(1-isocyano-2-methoxy-2-methylpropane) tetrafluoroboranuide
SMILES
[Cu+].F[B-](F)(F)F.COC(C)(C)C[N+]#[C-].COC(C)(C)C[N+]#[C-].COC(C)(C)C[N+]#[C-].COC(C)(C)C[N+]#[C-]

References

General References
  1. FDA Approved Drug Products: Cardiolite (Kit for the Preparation of Technetium Tc99m Sestamibi) for injection [Link]
ChemSpider
58827688
RxNav
1306061

Clinical Trials

Clinical Trials
Clinical Trial & Rare Diseases Add-on Data Package
Explore 4,000+ rare diseases, orphan drugs & condition pairs, clinical trial why stopped data, & more. Preview package
PhaseStatusPurposeConditionsCountStart DateWhy Stopped100+ additional columns
4CompletedDiagnosticCoronary Artery Disease (CAD) / Type 1 Diabetes Mellitus1somestatusstop reasonjust information to hide
3CompletedDiagnosticMucocutaneous Lymph Node Syndrome1somestatusstop reasonjust information to hide
0Active Not RecruitingDiagnosticEstrogen Receptor Negative / HER2 negative / Progesterone Receptor Negative / Triple Negative Breast Carcinoma1somestatusstop reasonjust information to hide
Not AvailableCompletedDiagnosticBreast Cancer2somestatusstop reasonjust information to hide
Not AvailableTerminatedDiagnosticIschemic Heart Disease / Myocardial Infarction1somestatusstop reasonjust information to hide

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
Injection, powder, for solution; kitIntravenous1 MG
Injection, powder, lyophilized, for solutionIntravenous0.5 mg
Kit1 mg
Injection, powder, lyophilized, for solutionIntravenous1 mg/vial
Injection, powder, lyophilized, for solutionIntravenous1 mg/1mL
Injection, powder, lyophilized, for solutionIntravenous1 mg
Kit500 Mikrogramm
Kit
Injection, powder, lyophilized, for solutionIntravenous1.5 mg/1
Injection, powder, for solutionIntravenous1.0 mg
Injection, powder, for solutionIntravenous1 MG/vial
Injection, powder, for solutionIntravenous bolus1 mg
InjectionIntravenous1 mg/1mL
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0366 mg/mLALOGPS
logP2.94ALOGPS
logP-1.3Chemaxon
logS-3.8ALOGPS
pKa (Strongest Acidic)16.14Chemaxon
pKa (Strongest Basic)-4.2Chemaxon
Physiological Charge1Chemaxon
Hydrogen Acceptor Count1Chemaxon
Hydrogen Donor Count0Chemaxon
Polar Surface Area13.59 Å2Chemaxon
Rotatable Bond Count8Chemaxon
Refractivity41.61 m3·mol-1Chemaxon
Polarizability12.7 Å3Chemaxon
Number of Rings0Chemaxon
Bioavailability1Chemaxon
Rule of FiveNoChemaxon
Ghose FilterNoChemaxon
Veber's RuleYesChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available
Chromatographic Properties
Collision Cross Sections (CCS)
Not Available

Drug created at June 21, 2018 16:28 / Updated at February 13, 2021 10:53